Literature DB >> 20953568

[Isolated systolic hypertension. An independent disease].

J Scholze1.   

Abstract

Hypertension can be classified based on certain criteria, such as severity, existence of specific end-organ damage, or the dominant blood pressure subphenotype so that isolated diastolic hypertension (IDH), mixed systolic-diastolic hypertension (SDH), and isolated systolic hypertensive (ISH) states can be defined. The FRAMINGHAM study was the first to demonstrate a continuous increase of systolic blood pressure with age and a peak of diastolic pressure between 55 and 65 years of age. This results not only in a high prevalence of hypertension of approximately 50-80% beyond the age of 60 but also in a disproportionately high increase in isolated systolic hypertension. ISH develops either as a new condition mostly from the group of primary high-normal blood pressure or secondly through burnout of existing systolic-diastolic hypertension with highly progressive vascular ageing.The pathophysiological background lies in remodeling processes in the macrovascular and microvascular compartments with stiffening of conduit and peripheral arterial vessels. In clinical practice these processes are easy to measure by determining pulse wave velocity (PWV), the augmentation index, and pulse pressure. These parameters are closely related to cardiovascular and cerebrovascular morbidity and mortality ISH is not only a hypertension subphenotype but often indicates significant organ damage or may even be considered to be a secondary form of hypertension characterized by remodeled and stiffened arterial vessel walls and this condition is difficult to treat. It appears therefore that ISH warrants special therapeutic strategies with a focus on antiproliferative, antistiffening, anti-atherosclerotic, and vasodilating actions. As a result of the available data from the results of treatment studies it appears that renin-angiotensin system (RAS) blockers and calcium channel blockers (CCBs) are the preferred drugs for treatment of this condition.

Entities:  

Mesh:

Year:  2010        PMID: 20953568     DOI: 10.1007/s00059-010-3390-7

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  37 in total

1.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

Authors:  L Liu; J G Wang; L Gong; G Liu; J A Staessen
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

2.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

3.  Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM.

Authors:  Gerd Assmann; Paul Cullen; Thomas Evers; Dieter Petzinna; Helmut Schulte
Journal:  Eur Heart J       Date:  2005-09-01       Impact factor: 29.983

4.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Isolated diastolic hypertension. A favorable finding among young and middle-aged hypertensive subjects.

Authors:  J Fang; S Madhavan; H Cohen; M H Alderman
Journal:  Hypertension       Date:  1995-09       Impact factor: 10.190

Review 7.  Pulse pressure, arterial stiffness and wave reflections (augmentation index) as cardiovascular risk factors in hypertension.

Authors:  Michel E Safar
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-02

8.  Thiazide diuretics, endothelial function, and vascular oxidative stress.

Authors:  Ming-Sheng Zhou; Ivonne Hernandez Schulman; Edgar A Jaimes; Leopoldo Raij
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

9.  [Pulse pressure in the therapeutic management of hypertension?].

Authors:  Jürgen Scholze
Journal:  Herz       Date:  2004-05       Impact factor: 1.443

Review 10.  Isolated diastolic hypertension.

Authors:  Thomas G Pickering
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Nov-Dec       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.